Publications (96) María Eugenia Alonso Sarasquete publications

2024

  1. Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient

    Biomedicines, Vol. 12, Núm. 1

2023

  1. Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level

    Disease models & mechanisms, Vol. 16, Núm. 8

  2. Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

    Cancers, Vol. 15, Núm. 14

  3. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

2022

  1. A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

    Journal of Visualized Experiments, Vol. 2022, Núm. 187

  2. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma

    Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871

  3. MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

2021

  1. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852

  2. Common gene variants within 3′-untranslated regions as modulators of multiple myeloma risk and survival

    International Journal of Cancer, Vol. 148, Núm. 8, pp. 1887-1894

  3. Evaluation of a worldwide EQA scheme for complex clonality analysis of clinical lymphoproliferative cases demonstrates a learning effect

    Virchows Archiv, Vol. 479, Núm. 2, pp. 365-376

  4. Genetic complexity impacts the clinical outcome of follicular lymphoma patients

    Blood Cancer Journal

  5. Genetically determined telomere length and multiple myeloma risk and outcome

    Blood Cancer Journal, Vol. 11, Núm. 4

  6. Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping

    British Journal of Haematology, Vol. 195, Núm. 4, pp. 542-551

  7. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders

    Blood Advances, Vol. 5, Núm. 16, pp. 3188-3198

2020

  1. A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients

    Journal of Molecular Diagnostics, Vol. 22, Núm. 1, pp. 60-71

  2. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

  3. Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder

    Leukemia and Lymphoma

  4. Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients

    British Journal of Haematology, Vol. 189, Núm. 4, pp. 718-730

  5. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

  6. Reply to Brown et al: ‘Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis’

    Leukemia and Lymphoma